Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)

Timeline

Start

2012-06-30

Primary completion

2014-02-28

Completion

2014-03-31

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs Vilazodone 40mg; p = 0.0156; Least Squares Mean Difference -1.80 (95% CI -3.26 to -0.34); MMRM NCT01629966 ↗

Publications

• Khan A, Durgam S, Tang X, Ruth A, Mathews M, Gommoll CP. Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. Prim Care Companion CNS Disord. 2016 Apr 28;18(2):10.4088/PCC.15m01904. doi: 10.4088/PCC.15m01904. eCollection 2016.
• Gommoll C, Durgam S, Mathews M, Forero G, Nunez R, Tang X, Thase ME. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder. Depress Anxiety. 2015 Jun;32(6):451-9. doi: 10.1002/da.22365. Epub 2015 Apr 17.

Drugs

Indications